BioCryst Pharmaceuticals, Inc.
BCRX$1.26B
Small CapNASDAQBiological Products, (No Diagnostic Substances)Healthcare🇺🇸North AmericaDURHAM580 employees
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
BCRX News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
No drugs found in this phase.
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply